Association of Anti-EGFR Antibody and MEK Inhibitor in Gynecological Cancer Harboring RAS Mutation: A Case Series
Authors:
- Julie NiogretJNJulie Niogret
- Valentin DerangèreVDValentin Derangère
- Corentin RichardCRCorentin Richard
- Lisa NuttinLNLisa Nuttin
- François GhiringhelliFrançois Ghiringhelli
- Laure FavierLFLaure Favier
- Leila Bengrine LefevreLLLeila Bengrine Lefevre
- Anthony BergeronABAnthony Bergeron
- Laurent ArnouldLALaurent Arnould
- Romain BoidotRBRomain Boidot
Open Access
- 19 March 2022
- journal article
- case report
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (6) , 3343
Abstract
Low-grade serous carcinoma represents a minority of serous carcinoma. Although they have better prognosis than high-grade serous carcinoma, they respond poorly to chemotherapy. Thus, it appears necessary to find other treatments such as targeted therapies. Since RAS or RAF mutations occur frequently in low-grade serous carcinoma and lead to constitutively activated MAPK cascade, MEK inhibition should be effective in the treatment of low-grade serous carcinoma. So, we wanted to evaluate the clinical benefit of MEK inhibitors in the management of advanced-stage low-grade serous carcinoma harboring KRAS or NRAS mutation. We report a case series of three women with advanced-stage low-grade serous carcinoma harboring RAS mutation who had stabilization of their disease during several months under targeted therapy combining anti-EGFR antibody and MEK inhibitor. We performed in vitro experiments, confirming the effectiveness of MEK inhibitor on the KRAS-mutated OVCAR-5 cell line, and the constitutively activation of MAPK cascade in RAS-mutated carcinoma. However, it seems that the anti-EGFR antibody does not provide any additional benefit. After whole exome analysis is carried out on the patient with the shortest response, we observed the appearance of RB1 loss-of-function mutation that could be a mechanism of resistance to MEK inhibitors in RAS- of RAF-mutated cancers. The MEK inhibitor is effective in the advanced stages of low-grade serous carcinoma harboring RAS mutation with acceptable tolerance. RB1 loss could be a mechanism of resistance to MEK inhibitors in RAS-mutated low-grade serous carcinoma.Keywords
This publication has 16 references indexed in Scilit:
- Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancerOncotarget, 2016
- Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genesOncotarget, 2015
- MEK1/2 inhibitors in the treatment of gynecologic malignanciesGynecologic Oncology, 2014
- Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 studyThe Lancet Oncology, 2013
- Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring V600EBRAFOncogene, 2011
- BRAF Mutation Is Rare in Advanced-Stage Low-Grade Ovarian Serous CarcinomasThe American Journal of Pathology, 2010
- Low-grade serous ovarian cancer: a unique diseaseCurrent Oncology Reports, 2008
- Clinical Behavior of Stage II-IV Low-Grade Serous Carcinoma of the OvaryObstetrics & Gynecology, 2006
- Mutations in BRAF and KRAS Characterize the Development of Low-Grade Ovarian Serous CarcinomaJNCI: Journal of the National Cancer Institute, 2003
- The Raf/MEK/ERK pathway: new concepts of activationBiology of the Cell, 2001